Cetuximab in colon cancer [2] (multiple letters)

New England Journal of Medicine

Volumn 351, Issue 15, 2004, Pages 1575-1576

  Holmer, Alan F ^a   Martin, Michael J ^b   Costa, Andry F ^c   Sander, Guilherme B ^c   Picon, Paulo D ^c   Schrag, Deborah ^d   Chau, Ian ^e   Cunningham, David ^e  

^a Pharmaceut Res Manufacturers Amer   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MINISTÉRIO DA SAÚDE   (Brazil)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; COLON CANCER; COST OF ILLNESS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG USE; HEALTH CARE AVAILABILITY; HEALTH CARE NEED; HUMAN; INVESTMENT; LETTER; MONEY; PATIENT CARE; PRIORITY JOURNAL; DRUG INDUSTRY; ECONOMICS; MEDICAL RESEARCH; MORTALITY; NEOPLASM; NOTE; SOCIOECONOMICS; COLORECTAL TUMOR; DRUG ANTAGONISM; QUALITY OF LIFE; COMPARATIVE STUDY; OUTCOME ASSESSMENT;

ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; DRUG COSTS; DRUG INDUSTRY; HUMANS; NEOPLASMS; VALUE OF LIFE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; QUALITY OF LIFE; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 19544361839     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200410073511519     Document Type: Letter

References (0)